Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity.
Wass R, Hochmair M, Kaiser B, Grambozov B, Feurstein P, Weiß G, Moosbrugger R, Sedlmayer F, Lamprecht B, Studnicka M, Zehentmayr F. Wass R, et al. Among authors: sedlmayer f. Cancers (Basel). 2022 Jun 30;14(13):3226. doi: 10.3390/cancers14133226. Cancers (Basel). 2022. PMID: 35804997 Free PMC article.
High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC.
Grambozov B, Stana M, Kaiser B, Karner J, Gerum S, Ruznic E, Zellinger B, Moosbrugger R, Studnicka M, Fastner G, Sedlmayer F, Zehentmayr F. Grambozov B, et al. Among authors: sedlmayer f. Cancers (Basel). 2022 Jan 23;14(3):573. doi: 10.3390/cancers14030573. Cancers (Basel). 2022. PMID: 35158841 Free PMC article. Review.
Carbon Monoxide Diffusing Capacity (DLCO) Correlates with CT Morphology after Chemo-Radio-Immunotherapy for Non-Small Cell Lung Cancer Stage III.
Stana M, Grambozov B, Gaisberger C, Karner J, Ruznic E, Berchtold J, Zellinger B, Moosbrugger R, Studnicka M, Fastner G, Sedlmayer F, Zehentmayr F. Stana M, et al. Among authors: sedlmayer f. Diagnostics (Basel). 2022 Apr 19;12(5):1027. doi: 10.3390/diagnostics12051027. Diagnostics (Basel). 2022. PMID: 35626183 Free PMC article.
DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.
Wurstbauer K, Deutschmann H, Dagn K, Kopp P, Zehentmayr F, Lamprecht B, Porsch P, Wegleitner B, Studnicka M, Sedlmayer F. Wurstbauer K, et al. Among authors: sedlmayer f. Radiat Oncol. 2013 Mar 5;8:49. doi: 10.1186/1748-717X-8-49. Radiat Oncol. 2013. PMID: 23497555 Free PMC article.
DART-bid for loco-regionally advanced NSCLC : Summary of acute and late toxicity with long-term follow-up; experiences with pulmonary dose constraints.
Wurstbauer K, Zehentmayr F, Deutschmann H, Dagn K, Exeli AK, Kopp P, Porsch P, Maurer B, Studnicka M, Sedlmayer F. Wurstbauer K, et al. Among authors: sedlmayer f. Strahlenther Onkol. 2017 Apr;193(4):315-323. doi: 10.1007/s00066-016-1095-4. Epub 2017 Jan 23. Strahlenther Onkol. 2017. PMID: 28116446 Free PMC article. Clinical Trial.
184 results